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Abstract
Background Acoustic radiation force impulse (ARFI) imag-
ing) is correlated with histopathological findings using
METAVIR and semiquantitative scoring system (SSS) criteria
for liver fibrosis.
Objective To compare acoustic radiation force impulse imaging
with biopsy results in the evaluation of liver fibrosis in children.
Materials and methods Children with chronic liver disease
and healthy children underwent acoustic radiation force impulse
imaging liver measurements. ARFI gives a shear-wave velocity
corresponding to tissue elasticity. In 39 children with liver
disease, the values obtained were correlated with biopsy results.
Receiver-operating characteristic (ROC) curves were used to
determine the reliability of ARFI in estimating liver fibrosis in
children.
Results ARFI mean value was 1.12 in the healthy group and
1.99 in children with chronic liver disease. ROC curves
show that an ARFI cutoff of 1.34 m/s is predictive of both
METAVIR and SSS scores with a sensitivity of SSS >
2:0.85; METAVIR > F0:0.82. A cutoff of 2 m/s yielded a
sensitivity of 100% to detect SSS > 4 or METAVIR > F2.
Conclusion Acoustic radiation force impulse imaging is a
reliable, noninvasive and rapid method to estimate moderate
to severe liver fibrosis in children. It might prove useful to
clinicians for fibrosis monitoring in children with liver dis-
ease and postpone the time of liver biopsy.
Keywords Liver fibrosis . ARFI elastography . Liver
disease . Child
Introduction
Chronic liver diseases in children have various aetiologies,
including congenital, metabolic, toxic and infectious [1]. Most
liver diseases diagnosed in childhood progress to fibrosis and
ultimately cirrhosis warranting liver transplantation. Children
with chronic liver disease need regular monitoring of the pro-
gression of their liver disease [2]. Historically, the tools used
have been clinical examination, blood tests, liver US and, in
some cases, liver biopsy [3, 4]. Biopsy is considered the gold
standard, but comes with limitations and risks. First, it only
yields a semiquantitative assessment and can be subject to
sampling error. Second, it is an invasive technique often requir-
ing general anaesthesia or sedation in children, and it is associ-
ated with the risk of severe complications.
Noninvasive techniques for measuring liver fibrosis are
poorly developed in children. They consist of biochemical
assays such as the Fibrotest (BioPredictive, Paris, France)
and APRI (aspartate transaminase-to-platelet ratio index)
but results are inconclusive and vary widely across studies
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[5]. Transient elastography, known as FibroScan (Echosens,
Paris, France), measures liver fibrosis by US elastography
[6, 7]. This technique is mainly used in adults and comes
with its own set of limitations [8]. The FibroScan is not guided
by real-time US imaging and has an unchangeable depth of
measurement. Until recently, the size of the probe used in adults
was not adapted to children. The paediatric probe has only been
marketed for a short time, and studies with the new probe are
scarce [9]. Studies with the adult probe have demonstrated the
risk of overestimating fibrosis. Furthermore, along with the size
being inappropriate for children, the shock wave is often not
adapted to the morphology of infants and small children youn-
ger than 4 years of age [7]. Acoustic radiation force impulse
(ARFI) is a new method to assess tissue elasticity. It has the
advantage of being coupled with the conventional US imaging
in real time, and the examiner can choose the region of interest.
ARFI is a measure of the speed of a shear wave in the
examined tissue, expressed in m/s. The principle of elasticity
is based on the Young modulus with the formula: E03ρV2 (E
elasticity’s modulus, V speed, ρ density of the tissue). ARFI
imaging yields the only direct variable, the propagation ve-
locity of the wave. Therefore, ARFI does not take into account
liver density (ρ), a constant in Young’s modulus but one that is
not applicable to human tissues, whose density is subject to
change. The aim of this study was to determine the congru-
ence between ARFI scores and fibrosis scores in children with
liver disease or following liver transplantation.
Materials and methods
Patients
Over a period of 2 years, 103 healthy controls (2 weeks to
17 years old) and 117 children with liver disease (3 weeks to
17 years old) underwent an abdominal US exam coupled
with an assessment of tissue elasticity using ARFI imaging.
The control population underwent abdominal US for any
reason other than liver diseases. Prior to ARFI measurements,
US of the liver, gallbladder, pancreas, spleen and biliary tract
was performed to rule out any pre-existing liver disease. The
control children or guardians were asked that the child be
taking no medication. The inclusion criterion was the absence
of known liver disease, based on history and US findings.
In the children with liver disease, the diagnoses included
biliary atresia, congenital fibrosis-cholestasis, Alagille syn-
drome, Caroli disease, choledochal cyst, α-1 antitrypsin
deficiency, progressive familial intrahepatic cholestasis
(PFIC), viral hepatitis, lymphoma, glycogenosis, fructosae-
mia, Wilson disease, cystic fibrosis, mesenterico-caval shunt
and status post liver transplant. All children or legal guard-
ians were informed of the study and gave written consent.
The study was approved by the ethics committee of our
institution (CER No. 10-248).
ARFI imaging is performed using a Virtual Touch Tissue
Quantification scanner (Siemens Medical Solutions, Erlan-
gen, Germany), a module of a standard US imaging Acuson
S2000 (Siemens). ARFI uses a high-energy US pulse-
producing mechanical excitation along the acoustic wave
propagation and the result is expressed in m/s. Speed
increases as tissue elasticity decreases.
In our paediatric practice, we use two probes: a convex 4-
MHz and a linear 9-MHz probe. The choice of the probe is
dependent on age and body size.We usually use a 9-MHz probe
for abdominal US in children younger than 5 years. Using a
high-frequency probe in young children allows for a better
analysis of the liver parenchyma, which in turn allows for better
positioning of the region of interest (ROI) away from vessels or
bile ducts, due to their relatively superficial position. There is no
significant difference in ARFI values between the two probes
and at different ROI depths (3–5 cm) in children [10].
Depending on the probe, the ROI we used was an area of
5 × 4 mm (9 MHz) or 5 × 10 mm (4 MHz). The ROI was
placed in the right liver lobe or in the transplanted liver, far
from a visible vessel or bile duct. Each child was measured
five times and the mean was calculated. The measurements
were performed by two senior radiologists (M.A. and S.H.,
who have one year of experience with the ARFI technique)
who were blinded to the histology results.
Liver biopsy analysis
Needle or surgical liver biopsies were performed for clinical
reasons such as high liver enzymes or as part of follow-up
protocol. Biopsies were routinely fixed in 10% buffered
formalin and were paraffin-embedded. For routine histolog-
ical examination, 3-μm-thick sections were stained with
haematoxylin-eosin. Routine special stains consisted of
Masson trichrome for fibrosis evaluation, reticulin stain for
liver architecture and fibrosis evaluation, Perl blue for hae-
mosiderin, and PAS diastase. In the absence of a specifically
validated score for fibrosis evaluation in children with var-
ious underlying disorders, two complementary scoring sys-
tems were used, METAVIR and semiquantitative scoring
system (SSS). First, biopsies were evaluated using the
METAVIR [11], a scoring system validated for hepatitis C
fibrosis staging in adults. Five stages of fibrosis are recog-
nised: F0 is no portal fibrosis; F1 is portal fibrosis without
septa; F2 is portal fibrosis with few septa, F3 is portal
fibrosis with numerous septa but no cirrhosis and F4 indi-
cates cirrhosis. Because centrilobular vein and perisinusoi-
dal fibrosis is not specifically addressed by the METAVIR
staging system, we also applied the SSS for evaluation of
hepatic fibrosis. The SSS score adds a description to liver
damage [12]. The SSS assesses portal tract fibrosis, the
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number and width of septa, and also the severity of central
vein and perisinusoidal fibrosis. The different items are
scored as outlined in Table 1, the chosen value of each item
representing the most representative lesion of the sample. A
minimal biopsy length of 10 mm and a minimum of five
portal tracts per biopsy were required for correct histological
assessment of needle biopsies. Liver biopsy interpretation
was performed by two senior pathologists (A.L.R. and
L.R.B.) blinded to the ARFI imaging results.
Statistical analysis
Descriptive statistics of ARFI imaging values for healthy
children and for each METAVIR score were provided using
the mean, standard deviation, median, median absolute differ-
ence (a measure of variability associated with the median, in the
same way that the standard deviation is associated with the
mean), minimum and maximum values. Mann–WhitneyU test
was used to compare ARFI values in healthy children and in
children with liver disease as well as in each consecutive
METAVIR score (e.g. healthy controls vs. F0 score, F0 vs. F1
group, F1 vs. F2 group).
The diagnostic accuracy of ARFI imaging to predict
METAVIR or SSS scores was assessed by means of
receiver-operating characteristic (ROC) curves. ROC curves
plot the sensitivity of ARFI imaging (i.e. the proportion of
children with a METAVIR score above F0 correctly detected
by the ARFI) against the specificity of ARFI imaging (i.e. the
proportion of children with a METAVIR score of F0 correctly
classified by ARFI as healthy) for each value of ARFI. Two
degrees of liver fibrosis severity were assessed: METAVIR
score above F0 (or a SSS score ≥ 3) and METAVIR score of
F3 or F4 (or a SSS score ≥ 5). The threshold was determined
according to two principles, the first using the Youden index,
which maximises sensitivity and specificity, and the second
providing perfect sensitivity to detect fibrosis while still
allowing the possibility to rule out fibrosis in some children.
The rationale for the second threshold is that ARFI imaging is
a noninvasive and rapid procedure and, as such, should ideally
be used as a screening method, thus requiring high sensitivity.
Analyses were performed using R 2.15.1 [13].
Results
Among the 117 children with liver disease, we recruited
children who had a liver biopsy within 3 months of ARFI
analysis, which accounted for 39 children. The low number of
biopsies in our series (compared with adult studies) is a result
of the fact that even in children with liver disease biopsies are
more difficult to obtain; biopsy is considered invasive and
anaesthesia is often needed. The decision to perform a biopsy
(percutaneous or surgical) was clinically driven and indepen-
dent of the present study.
A total of 142 children were enrolled in this study, 103
healthy controls (mean age 75.1 months, SD062.3; 55 boys,
48 girls) and 39 children with liver disease (ages 1 month to
14 years, mean 66.8 months, SD059.0; 26 boys and 13 girls).
The 39 children had liver biopsy done within 3 months of
ARFI values. The liver diseases of these 39 children are
detailed in the Table 2; the majority had liver transplants.
The correlation between METAVIR and SSS scores in the
children with liver disease was 0.94 among the whole sample
and 0.95 among just the childrenwith liver disease, showing that
METAVIR and SSS scores are in agreement on liver fibrosis
severity.
ARFI imaging mean score was 1.12 m/s in the healthy
group (SD, 0.13; median, 1.11; minimum, 0.73; maximum,
1.45) and 1.99 m/s (SD, 0.99; median, 1.67; minimum, 0.77;
Table 1 Semiquantitave scoring system (SSS)
Centrilobular vein (CLV) 0: normal or absence of vein (cirrhosis)
1: moderately thickened
2: markedly thickened
Perisinusoidal fibrosis (PS) 0: normal
1: localised fibrosis
2: diffuse fibrosis
Portal tract (PT) 0: normal
1: enlarged without septa
2: enlarged with septa
3: cirrhosis
Number of septa (NS) 0: none
1: ≤ 6 septa/10 mm
2: > 6 septa/10 mm
3: nodular organisation
Width of septa (WS) 0: thin and/or incomplete
1: thick and loose connective matrix
2: very thick and dense
connective matrix
3: > 2/3 biopsy area
The final score is calculated: SSS ¼ CLVþ PSþ PTþ 2 NSxWSð Þ
and ranges from 0 to 37
Table 2 Diagnoses in 39 children with liver disease included in the
study
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maximum, 4.70) in children with liver disease (P < 0.001).
Table 3 provides the descriptive statistics for the healthy
group and each METAVIR score group as well as tests
comparing ARFI imaging scores between each consecutive
METAVIR score.
Correlations between ARFI imaging values and META-
VIR (F0-F4) are shown in Fig. 1. ARFI imaging mean
scores (n, SD) were 1.47 (n 0 11, 0.47) for F0, 1.65
(n 0 11, 0.60) for F1, 2.30 (n 0 6, 1.36) for F2, 2.61
(n 0 8, 1.25) for F3, and 2.81 (n 0 3, 0.61) for F4.
Association betweenARFI values and SSS scores are shown
in Fig. 2. Mean SSS score in the children with liver disease was
5.33 (SD, 5.40; median, 4; minimum, 0; maximum, 22).
The box plots of ARFI imaging values for each category of
biopsies with METAVIR scores show an increase in ARFI
values evident in fibrosis stages F3 and F4. ARFI imaging
values present a slight increase in the F2 stage. By contrast, it
seems difficult to distinguish stage F0 from stage F1. We found
the same conclusions concerning the association of ARFI and
the SSS. ROC curves (Fig. 3) show that sensitivity rapidly
drops for both METAVIR and SSS scores when comparing
F0 (SSS of 0–2) and ≥ F1 (SSS ≥ 3). The threshold to detect all
children with some liver fibrosis according to the biopsy (100%
sensitivity threshold) would be 1.0, and the specificity at this
threshold would be very low. The Youden index threshold
(maximising both sensitivity and specificity) is 1.34 (Table 4),
yielding a sensitivity of 0.85 for SSS and 0.82 for METAVIR
and specificity of 0.46 for SSS and 0.45 for METAVIR. By
using this threshold for screening purposes, five children with
liver disease out of 39 would have been missed: four children
with a positive SSS and METAVIR scores and one child with
a positiveMETAVIR. Among the four children with a positive
SSS score, two had a score of 3 and two had a score of 4.
Among the five childrenwith a positiveMETAVIR score, four
had F1 scores and one had an F2 score. Thus, according to this
cutoff, children not detected by the ARFI method would be in
the initial stages of fibrosis.
If ARFI measurement is used to compare children with
mild fibrosis against children with severe fibrosis (i.e.
METAVIR ≤ F2 vs. ≥ F3 or SSS score < 5 vs. ≥ 5), ROC
curves show that sensitivity remains at 100% (children
correctly identified: 16 of 16 with an SSS score ≥ 5, 11 of
Table 3 Descriptive statistics of ARFI scores in healthy children and in children with liver disease by METAVIR scores
Group n Mean (SD) Median (MAD) Range P value
Healthy 103 1.12 (0.13) 1.11 (0.10) 0.73–1.45 –
METAVIR F0 11 1.47 (0.47) 1.54 (0.56) 0.77–2.29 0.008
METAVIR F1 11 1.65 (0.60) 1.42 (0.42) 1.07–2.76 0.70
METAVIR F2 6 2.30 (1.36) 1.70 (0.58) 1.06–4.70 0.30
METAVIR F3 8 2.61 (1.25) 2.23 (1.28) 1.36–4.70 0.61
METAVIR F4 3 2.89 (0.61) 2.89 (0.89) 2.29–3.50 0.78
P values are given by the Mann–Whitney U test between the previous group and the group considered
SD standard deviation, MAD median absolute deviation (measure of variability)
Fig. 1 ARFI and METAVIR.
Box plots of ARFI imaging
scores for each METAVIR
category. Number of children
per category is indicated on top
of the figure. The ref. group is
the normal population; F0 to F4
represent children with liver
disease with histologically
increasing levels of liver
fibrosis
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11 with a METAVIR score ≥ F3, with a specificity of 39.1%
for SSS and 32.1% for METAVIR). In other words, 9 of 23
children with an SSS score < 5 were correctly ruled out, and
9 of 28 children with a METAVIR score ≤ F2 were correctly
ruled out. The 100% sensitivity threshold between mild and
severe is 2.0 m/s.
Discussion
The grading of liver fibrosis is essential for the monitoring
and appropriate treatment of children with chronic liver
disease. Even if biopsy is considered the gold standard for
assessing liver fibrosis [14], it is unthinkable to use it as the
only tool in monitoring these pathologies in children. De-
velopment of noninvasive techniques is essential [15].
FibroScan and serum markers are among the most current
noninvasive techniques used in adults in predicting fibrosis
[16] and recently the ARFI imaging technique has emerged.
In children, the FibroScan has several disadvantages: fixed
depth measurement and absence of real-time US guidance,
and it cannot be performed in obese children or children
with ascites [6, 17–19]. Further, blood markers of liver
fibrosis (Fibrotest, APRI) are poorly evaluated and impre-
cise in children in current literature.
ARFI imaging elastography is a noninvasive technology
to evaluate hepatic fibrosis (Fig. 4) that has proved advan-
tageous in adults. To assess its ability to reliably identify and
quantify liver fibrosis, ARFI values in adults have been
compared to METAVIR or Ludwig scoring [20–23].
We report our ARFI imaging elastography experience in
assessing the degree of hepatic fibrosis in children with
chronic liver disease and liver transplant with pathological
correlation based on two histological scoring systems,
METAVIR and the SSS.
In our study, ARFI imaging values were clearly in-
creased in METAVIR fibrosis stages F3 and F4 (Fig. 1).
ARFI values showed a slight increase in the F2 stage. By
contrast, it was difficult to distinguish F0 from F1, confirm-
ing studies in adults [24, 25]. The same applies to the
Fig. 2 ARFI and SSS. Scatter plot of SSS scores as a function of
ARFI imaging scores for healthy children and for children with liver
disease. The horizontal line indicates the cutoff value for ARFI to
maximise sensitivity and specificity
Fig. 3 ROC curves of ARFI
imaging scores for METAVIR
and SSS scores
Table 4 SSS/METAVIR with ARFI scores: Youden’s index threshold
(maximising both sensitivity and specificity) is 1.34
SSS METAVIR Total
3–28 0–2 F1–F4 F0
ARFI > 1.34 22 7 23 6 29
ARFI < 1.34 4 6 5 5 10
Total 26 13 28 11 39
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association between ARFI and the SSS (Fig. 2). ROC curves
show that ARFI imaging scores are predictive of both
METAVIR and SSS scores (Fig. 3). Based on the Youden
index, a cutoff of 1.34 m/s maximises sensitivity and spec-
ificity (Table 2), yielding a sensitivity of 0.85 for the SSS
and 0.82 for METAVIR.
A similar cutoff value of 1.31 m/s was reported in the
only other paediatric study to date examining the relation-
ship between ARFI imaging and liver fibrosis [26]. How-
ever, that study differs from ours in four respects. First, the
populations differed in that only ours includes children post
liver transplant, which is a large share of any paediatric
hepatology practice. Second, there were technical differen-
ces: Noruegas et al. [26] used a 4-MHz probe, which is not
optimal in young children in our experience. Third, there
was a maximum interval of 1 year between biopsy and
ARFI evaluation in the Noruegas et al. [26] study, whereas
we selected children who had biopsy and ARFI within a 3-
month interval [27, 28]. The last point of contrast is that we
used METAVIR and SSS, while Noruegas et al. [26] used
the Batts and Ludwig score [29].
In paediatrics, there is no validated histological scoring
system for studying liver fibrosis. In adults, the METAVIR
and Ludwig scores are the most widely used but have
mainly been validated for fibrosis secondary to hepatitis C.
Because the interpretation of liver biopsies in children is
difficult because of the diversity of diseases, we chose to
apply the METAVIR score, which is considered the gold
standard in adults, and the SSS described by Chevallier et al.
[12], a more complicated but arguably more accurate scor-
ing system with respect to tissue changes.
The analysis of ROC curves with both METAVIR scores
and the SSS findings allowed us to establish a cutoff ARFI
value of 1.34 m/s for fibrosis stage > F0 in our paediatric
population. A cutoff of 2 m/s provided a sensitivity of 100% to
detect SSS > 4 orMETAVIR > F2 in our population. This is in
contrast with the meta-analysis in adults by Friedrich-Rust et
al. [30], wherein there was a cutoff of 1.34 m/s for F ≥ 2;
1.55 m/s for F ≥ 3, and 1.8 m/s for F 0 4. Adult studies have
the advantage of having a larger population with liver biop-
sies, so there are cutoffs in adults corresponding to various
degrees of fibrosis. Unfortunately, biopsies in children occur
more seldom and therefore the numbers are too small in this
study to allow for stratified cutoffs.
Nonetheless, it is safe to conclude that akin to what has
been described in adults, early stages of fibrosis are difficult
to detect by ARFI imaging because the measurements
obtained in early fibrosis are similar to those obtained in
normal liver. ARFI values should be interpreted with cau-
tion because of the limited specificity. However, abnormal
values should encourage frequent clinical follow-up and
serial ARFI imaging elastography. ARFI is not a substitute
for other means of detecting fibrosis, and correlation with
fibrosis blood tests must be continued in parallel to elastog-
raphy monitoring [30].
Although ours is the first study to include liver transplant
recipients in the population, thus widening the scope, it is
limited by the small number of children who met our crite-
rion of having had a biopsy. This is because liver biopsies
are less often performed in children with liver disease than
in their adult counterparts. Nonetheless, our study joins that
of Noruegas et al. [26] to confirm the feasibility and the
utility of ARFI imaging as a noninvasive technique to
measure liver elastography and assess liver fibrosis in
children.
Conclusion
ARFI elastography is a recent and clinically promising non
invasive technique to assess liver fibrosis in children with
chronic liver disease or liver transplants and can be used in
Fig. 4 US ARFI measurements. a ARFI imaging in a 4-month-old,
using a 9-MHz probe, shear-wave velocity 4.76 m/s at 2.5-cm depth.
METAVIR score in this child is F4. b ARFI in a 15-year-old boy, using
a 4-MHz probe, shear-wave velocity 1.55 m/s at 4.8-cm depth. META-
VIR score in this child is F2
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clinical practice. ARFI values increase with increasing he-
patic fibrosis but there are limitations in assessing initial
stages of fibrosis. ARFI imaging might help to reduce or
postpone the number of biopsies in some children. Given
the diversity of liver diseases in children, studies using
ARFI imaging in specific liver diseases in children might be
warranted.
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